TJC0434 series compounds are NADPH Oxidase (NOX) inhibitors that have been reported to have anti-fibrotic effects by the literature. Our series of NOX inhibitors have been proved to show much better NOX inhibiting activities than the current lead compounds by other international pharmas. In addition, our series of NOX inhibitors have demonstrated great performance in the PK, safety profiles (including MTD and off-target screenings) and some specific anti-inflammatory animal efficacy tests. More different animal efficacy and pharmacology mechanism studies are under process.